Cargando…

The MID1 Protein: A Promising Therapeutic Target in Huntington’s Disease

Huntington’s disease (HD) is caused by an expansion mutation of a CAG repeat in exon 1 of the huntingtin (HTT) gene, that encodes an expanded polyglutamine tract in the HTT protein. HD is characterized by progressive psychiatric and cognitive symptoms associated with a progressive movement disorder....

Descripción completa

Detalles Bibliográficos
Autores principales: Heinz, Annika, Schilling, Judith, van Roon-Mom, Willeke, Krauß, Sybille
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517220/
https://www.ncbi.nlm.nih.gov/pubmed/34659371
http://dx.doi.org/10.3389/fgene.2021.761714
_version_ 1784583965706813440
author Heinz, Annika
Schilling, Judith
van Roon-Mom, Willeke
Krauß, Sybille
author_facet Heinz, Annika
Schilling, Judith
van Roon-Mom, Willeke
Krauß, Sybille
author_sort Heinz, Annika
collection PubMed
description Huntington’s disease (HD) is caused by an expansion mutation of a CAG repeat in exon 1 of the huntingtin (HTT) gene, that encodes an expanded polyglutamine tract in the HTT protein. HD is characterized by progressive psychiatric and cognitive symptoms associated with a progressive movement disorder. HTT is ubiquitously expressed, but the pathological changes caused by the mutation are most prominent in the central nervous system. Since the mutation was discovered, research has mainly focused on the mutant HTT protein. But what if the polyglutamine protein is not the only cause of the neurotoxicity? Recent studies show that the mutant RNA transcript is also involved in cellular dysfunction. Here we discuss the abnormal interaction of the mutant HTT transcript with a protein complex containing the MID1 protein. MID1 aberrantly binds to CAG repeats and this binding increases with CAG repeat length. Since MID1 is a translation regulator, association of the MID1 complex stimulates translation of mutant HTT mRNA, resulting in an overproduction of polyglutamine protein. Thus, blocking the interaction between MID1 and mutant HTT mRNA is a promising therapeutic approach. Additionally, we show that MID1 expression in the brain of both HD patients and HD mice is aberrantly increased. This finding further supports the concept of blocking the interaction between MID1 and mutant HTT mRNA to counteract mutant HTT translation as a valuable therapeutic strategy. In line, recent studies in which either compounds affecting the assembly of the MID1 complex or molecules targeting HTT RNA, show promising results.
format Online
Article
Text
id pubmed-8517220
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85172202021-10-16 The MID1 Protein: A Promising Therapeutic Target in Huntington’s Disease Heinz, Annika Schilling, Judith van Roon-Mom, Willeke Krauß, Sybille Front Genet Genetics Huntington’s disease (HD) is caused by an expansion mutation of a CAG repeat in exon 1 of the huntingtin (HTT) gene, that encodes an expanded polyglutamine tract in the HTT protein. HD is characterized by progressive psychiatric and cognitive symptoms associated with a progressive movement disorder. HTT is ubiquitously expressed, but the pathological changes caused by the mutation are most prominent in the central nervous system. Since the mutation was discovered, research has mainly focused on the mutant HTT protein. But what if the polyglutamine protein is not the only cause of the neurotoxicity? Recent studies show that the mutant RNA transcript is also involved in cellular dysfunction. Here we discuss the abnormal interaction of the mutant HTT transcript with a protein complex containing the MID1 protein. MID1 aberrantly binds to CAG repeats and this binding increases with CAG repeat length. Since MID1 is a translation regulator, association of the MID1 complex stimulates translation of mutant HTT mRNA, resulting in an overproduction of polyglutamine protein. Thus, blocking the interaction between MID1 and mutant HTT mRNA is a promising therapeutic approach. Additionally, we show that MID1 expression in the brain of both HD patients and HD mice is aberrantly increased. This finding further supports the concept of blocking the interaction between MID1 and mutant HTT mRNA to counteract mutant HTT translation as a valuable therapeutic strategy. In line, recent studies in which either compounds affecting the assembly of the MID1 complex or molecules targeting HTT RNA, show promising results. Frontiers Media S.A. 2021-10-01 /pmc/articles/PMC8517220/ /pubmed/34659371 http://dx.doi.org/10.3389/fgene.2021.761714 Text en Copyright © 2021 Heinz, Schilling, van Roon-Mom and Krauß. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Heinz, Annika
Schilling, Judith
van Roon-Mom, Willeke
Krauß, Sybille
The MID1 Protein: A Promising Therapeutic Target in Huntington’s Disease
title The MID1 Protein: A Promising Therapeutic Target in Huntington’s Disease
title_full The MID1 Protein: A Promising Therapeutic Target in Huntington’s Disease
title_fullStr The MID1 Protein: A Promising Therapeutic Target in Huntington’s Disease
title_full_unstemmed The MID1 Protein: A Promising Therapeutic Target in Huntington’s Disease
title_short The MID1 Protein: A Promising Therapeutic Target in Huntington’s Disease
title_sort mid1 protein: a promising therapeutic target in huntington’s disease
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517220/
https://www.ncbi.nlm.nih.gov/pubmed/34659371
http://dx.doi.org/10.3389/fgene.2021.761714
work_keys_str_mv AT heinzannika themid1proteinapromisingtherapeutictargetinhuntingtonsdisease
AT schillingjudith themid1proteinapromisingtherapeutictargetinhuntingtonsdisease
AT vanroonmomwilleke themid1proteinapromisingtherapeutictargetinhuntingtonsdisease
AT kraußsybille themid1proteinapromisingtherapeutictargetinhuntingtonsdisease
AT heinzannika mid1proteinapromisingtherapeutictargetinhuntingtonsdisease
AT schillingjudith mid1proteinapromisingtherapeutictargetinhuntingtonsdisease
AT vanroonmomwilleke mid1proteinapromisingtherapeutictargetinhuntingtonsdisease
AT kraußsybille mid1proteinapromisingtherapeutictargetinhuntingtonsdisease